Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10932)
  2. Meeting Abstract (9499)
  3. Review (556)
  4. Book Section (417)
  5. Editorial (336)
  6. Guidelines (158)
  7. Correspondence (118)
  8. Conference Paper (107)
  9. Research Letter (61)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22242)
  2. GSK Faculty (5929)
  3. Genitourinary Oncology Service (5651)
  4. Survivorship Research (5226)
  5. Gastrointestinal Oncology Service (4692)
  6. Breast Medicine Service (4155)

More Groups

People
  1. Robert Motzer (1247)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (642)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5288)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (532)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5580)
  2. Elsevier Inc. (2662)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1043)
  6. Springer (981)

More Publishers

Results (22265)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician's choice (TPC) in relapsed small cell lung cancer (SCLC)
    Meeting Abstract

    Owonikoko, T. K.; Byers, L. A.; Cheng, Y.; Hayashi, H.; Paz-Ares, L. G.; Perol, M.; Turner, J.; Qian, M.; Garcia, C. R.; Godard, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer
    Meeting Abstract

    Gaillard, S.; Starodub, A.; O'Neil, B.; Mathews, C. A.; Dumbrava, E. E.; Friedman, C. F.; Swiecicki, P.; Oh, C.; Andreu, C.; Lee, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS)
    Meeting Abstract

    Grilley-Olson, J. E.; Allred, J. B.; Schuetze, S.; Davis, E. J.; Poklepovic, A. S.; Wagner, M. J.; Riedel, R. F.; Hartranft, A.; Welliver, M. X.; Berg, S. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient factors associated with chemotherapy modifications: Results from the Optimal Breast Cancer Chemotherapy Dosing (OBCD) study
    Meeting Abstract

    Kantor, E.; Bhimani, J.; Gallagher, G. B.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
    Meeting Abstract

    Dockery, L. E.; Slomovitz, B. M.; Musa, F.; Mathews, C. A.; Priebe, A. M.; Green, A.; Puechl, A.; Birrer, M. J.; Spirtos, N. M.; Ding, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma
    Meeting Abstract

    O'Reilly, E. M.; Wainberg, Z. A.; Fisher, G. A. Jr; Wolff, R. A.; Ko, A. H.; O'Hara, M. H.; Spencer, C. N.; Yu, J. X.; Da Silva, D. M.; Padron, L. J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study
    Meeting Abstract

    Langer, C. J.; Galot, R.; Prenen, H.; Hong, D. S.; Victoria, I.; Salgia, R.; Chenard-Poirier, M.; Furqan, M.; Chan, E.; Nolte-Hippenmeyer, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors
    Meeting Abstract

    Schoenfeld, A. J.; Warner, A. B.; Chesney, J. A.; Thomas, S. S.; Hamid, O.; In, G. K.; Shoushtari, A. N.; Samhouri, Y.; Hari, P. N.; Ramsingh, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)
    Meeting Abstract

    McKay, R. R.; Liu, L.; Pu, M.; Araneta, A.; Yuen, K. L.; Gomez, J.; Castano, N.; Ajmera, A.; Ye, H.; Pili, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient characteristics associated with primary prophylactic granulocyte colony-stimulating factor (G-CSF) use among women treated for early-stage breast cancer
    Meeting Abstract

    Gallagher, G. B.; O'Connell, K.; Bhimani, J.; Blinder, V. S.; Burganowski, R. P.; Griggs, J. J.; Kolevska, T.; Kroenke, C.; Laurent, C.; Liu, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save